ASTRAZEN vs DCAL: Stock Comparison
ASTRAZENECA PHARMA IND LT is the larger company by market capitalisation. ASTRAZENECA PHARMA IND LT shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ASTRAZEN leads 11; DCAL leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ASTRAZEN | DCAL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ASTRAZEN | DCAL |
|---|---|---|
| Live Price | ₹6,944 | ₹174.38 |
| Day Change | 0.05% | -1.47% |
| Volume | 6,489 | 1.23 L |
| 52-Week High | ₹9,849.5 | ₹321.95 |
| 52-Week Low | ₹6,835 | ₹128.5 |
| Distance from 52W High | -29.5% | -45.84% |
Valuation
| Metric | ASTRAZEN | DCAL |
|---|---|---|
| Market Cap | ₹17,288 Cr | ₹2,723 Cr |
| P/E Ratio | 101.61x | 172.04x |
| P/B Ratio | 19.75x | 0.42x |
| EPS | ₹15.17 | ₹-1.53 |
| Book Value | ₹349.12 | ₹425.87 |
| Dividend Yield | 0.52% | 0% |
Growth
| Metric | ASTRAZEN | DCAL |
|---|---|---|
| Revenue Growth (TTM YoY) | 20.4% | 18.9% |
| EPS Growth (TTM YoY) | -23% | -49.5% |
| Qtr Sales Growth | -69.99% | -91.58% |
| Qtr Profit Growth | -79.77% | 58.69% |
Profitability & Leverage
| Metric | ASTRAZEN | DCAL |
|---|---|---|
| ROE | 21.49% | 1.46% |
| ROCE | 44.9% | 1.52% |
| Net Margin | 8.24% | 2.51% |
| Operating Margin | 11.28% | 9.52% |
| Debt to Equity | 0x | 0.42x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ASTRAZEN | DCAL |
|---|---|---|
| Promoter Holding | 0% | 59.32% |
| FII Holding | 2.68%▼ 0.1 pp | 6.86%▼ 0.59 pp |
| DII Holding | 6.08%▲ 0.28 pp | 2.07%▲ 0.44 pp |
| Public Holding | 16.24%▼ 0.18 pp | 31.75%▲ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ASTRAZENECA PHARMA IND LT and DISHMAN CARBO AMCIS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.